BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05372419 (Lebrikizumab in Atopic Dermatitis and Skin of Color): BVCT ex-ante prediction vs. reported outcome

On 26 Nov 2022, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 11 Mar 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT05372419
Acronym
ADmirable
Drug Name
Lebrikizumab (LY3650150)
Drug MoA
IL-13 mAb inhibitor
Drug Modality
monoclonal antibody (mAb)
Drug Class
Best-In-Class
Therapeutic Area
Skin and Connective Tissue Diseases
Indication
Atopic Dermatitis and Skin of Color
Human Patients
80
Sponsor
Eli Lilly and Company
Phase
Phase 3

Prediction of , index 717

Prospective Prediction
Prediction Index
717
Prediction Date
Commercial Prediction
SUCCESS
Technical Prediction
SUCCESS

Readout of

Prediction Validation
Readout Date
Prediction To Readout
471 days in advance
Readout Data Interpretation
68% EASI75 and 46% EASI90 55% itch reduction and 39% clear of skin; which is superior to 49% EASI75 achieved by dupilumab.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
An Open-Label, 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Phase
Phase 3
Status
Completed
Enrollment
90
Lead sponsor
Eli Lilly and Company
Conditions
Atopic Dermatitis
Interventions
DRUG: Lebrikizumab
Design
Single group · None
Primary purpose
Treatment
Start
2023-01-12
Primary completion
2024-05-03
Completion
2025-02-17
Results first posted
2025-06-11
Primary outcomes
  • Percentage of Participants Achieving Eczema Area and Severity Index 75 (≥75% Reduction From Baseline in EASI) at Week 16 (Week 16)

NCT05372419 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials